Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Cash Flow PerformanceElevated
Percentile Rank100
3Y CAGR+38.3%
5Y CAGR+54.4%
Studio
Year-over-Year Change

Free cash flow yield

3Y CAGR
+38.3%/yr
Annual compound
5Y CAGR
+54.4%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
8.8x
Strong expansion
Streak
3 yr
Consecutive growthElevated
PeriodValueYoY Change
20257.99%+3.5%
20247.72%+0.9%
20237.66%+153.3%
20223.02%-42.6%
20215.27%+478.9%
20200.91%+126.0%
2019-3.50%-35.5%
2018-2.58%-153.8%
20174.80%+212.7%
2016-4.26%-